Vanguard Global Advisers
ZNTL icon

Vanguard Global Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vanguard Global Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Hold
21,725
– – ﹤0.01% 2757
2026
Q1 		$50.8K Buy
+21,725
New +$56.1K ﹤0.01% 3013

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Global Advisers's ZNTL Position: Q2 2026 in Review

Vanguard Global Advisers held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 21,725 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2757.

Vanguard Global Advisers first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Vanguard Global Advisers held 21,725 shares of Zentalis Pharmaceuticals worth $105K as of Q2 2026.
  • Vanguard Global Advisers left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2757 holding.
  • Vanguard Global Advisers first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.